Wellcome Trust and Merck join forces to develop vaccines for low income countriesBMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b3804 (Published 17 September 2009) Cite this as: BMJ 2009;339:b3804
- Lynn Eaton
A leading research trust and a major drug company have launched a £90m (€100m; $150m) initiative to boost research into vaccines for diseases that are prevalent in low income countries.
The Wellcome Trust and Merck have announced that they will jointly fund the creation of a new laboratory, to be based in India, that will develop affordable vaccine technology.
The MSD Wellcome Trust Hilleman Laboratories will be based in India and will be equally funded by the two organisations, which will also share decision making rights in the venture. It will operate as a not for profit company, developing new vaccines and improving existing products.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial